Ascensia Diabetes Care said today it inked a deal with Dexcom (NSDQ:DXCM) to integrate information from its Ascensia ContourNext One blood glucose monitoring system as part of Dexcom’s G5 continuous glucose monitoring system Medicare offering.
Through the deal, Parsippany, N.J.-based Ascensia’s tech will be included in the bundle, which is available to individuals with diabetes who are covered by Medicare and qualify for therapeutic CGM, the company said.
The Dexcom G5 is currently the only CGM approved by the FDA which meets criteria for a therapeutic CGM, Ascensia said.
“For those people with diabetes who are eligible to receive the G5 through Medicare, Ascensia is thrilled to become the partner of choice for calibration of the Dexcom G5 CGM System. We believe this combination will help improve diabetes management for people on Medicare who are eligible for therapeutic CGM,” Ascensia Diabetes Care US managing director Robert Schumm said in a prepared statement.
As part of the deal, Ascensia’s ContourNext One BGMS will be provided to qualified individual to provide “highly accurate readings for CGM calibration,” the company said.
“Continuous glucose monitoring is a rapidly growing technology, and Dexcom holds world class expertise in the development and delivery of CGM systems. We are delighted to partner with Dexcom to help this group of patients with their diabetes management, by providing them with our highly accurate ContourNext One BGMS as part of the bundle they receive,” Ascensia CEO Michael Kloss said in a prepared release.
“Dexcom is at the forefront of diabetes technology, and in Ascensia, we saw a business partner that matches our own commitment to best-in-class products and services for people with diabetes. With this agreement, we are pleased to begin offering a complete bundle to Medicare-eligible patients, enabling access to the Dexcom G5 CGM System as efficiently as possible,” Dexcom chief commercial officer Rick Doubleday said in a press release.
Last month, Ascensia said it inked a strategic alliance with Insulet (NSDQ:PODD) to integrate connectivity between Insulet’s next-gen Omnipod system with Ascensia’s Contour Next One blood glucose monitoring system.